[Skip to Content]
[Skip to Content Landing]
Article
November 3, 1989

Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex

Author Affiliations

the AZT Collaborative Working Group
From the University of Miami (Fla) (Dr Fischl); the University of California, San Diego (Dr Richman); Los Angeles County—University of Southern California, Los Angeles (Dr Causey); St Luke's—Roosevelt Hospital Center, New York, NY (Dr Grieco); the University of California, Los Angeles (Dr Bryson); Beth Israel Medical Center, New York (Dr Mildvan); Cornell University Medical College, New York (Dr Laskin); Harvard— New England Deaconess Hospital, Boston, Mass (Dr Groopman); the University of California, San Francisco (Dr Volberding); Harvard-Massachusetts General Hospital, Boston (Dr Schooley); the University of Illinois at Chicago (Dr Jackson); Duke University Medical Center, Durham, NC (Dr Durack); and Burroughs Wellcome Co, Research Triangle Park, NC (Drs Andrews, Nusinoff-Lehrman, and Barry). Dr Laskin is now with Merck Sharp and Dohme Research Laboratories, Rahway, NJ. Dr Jackson is now with the London (England) Hospital Medical College.

the AZT Collaborative Working Group
From the University of Miami (Fla) (Dr Fischl); the University of California, San Diego (Dr Richman); Los Angeles County—University of Southern California, Los Angeles (Dr Causey); St Luke's—Roosevelt Hospital Center, New York, NY (Dr Grieco); the University of California, Los Angeles (Dr Bryson); Beth Israel Medical Center, New York (Dr Mildvan); Cornell University Medical College, New York (Dr Laskin); Harvard— New England Deaconess Hospital, Boston, Mass (Dr Groopman); the University of California, San Francisco (Dr Volberding); Harvard-Massachusetts General Hospital, Boston (Dr Schooley); the University of Illinois at Chicago (Dr Jackson); Duke University Medical Center, Durham, NC (Dr Durack); and Burroughs Wellcome Co, Research Triangle Park, NC (Drs Andrews, Nusinoff-Lehrman, and Barry). Dr Laskin is now with Merck Sharp and Dohme Research Laboratories, Rahway, NJ. Dr Jackson is now with the London (England) Hospital Medical College.

JAMA. 1989;262(17):2405-2410. doi:10.1001/jama.1989.03430170067030
Abstract

We examined the long-term safety and efficacy of zidovudine therapy in 229 subjects with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex who previously participated in a placebo-controlled study of zidovudine. One hundred two placebo recipients (delayed treatment group) and 127 zidovudine recipients (original treatment group) were followed up while receiving zidovudine therapy for a mean of 21 months. Survival rates for the original treatment group were 84.5% and 57.6% at 12 and 21 months, respectively; for the delayed treatment group, 78.8% and 64.6% at 12 and 18 months, respectively; and 78.8% and 47.5% at 12 and 21 months, respectively, for 77 subjects with AIDS and 93.0% and 71.8%, respectively, for 50 subjects with AIDS-related complex in the original treatment group. Adverse reactions decreased over time and newly observed toxic reactions were unusual. The clinical course of these subjects suggests continued survival benefits with long-term zidovudine therapy.

(JAMA. 1989;262:2405-2410)

×